Business Wire

CA-C3.AI

9.11.2021 15:02:39 CET | Business Wire | Press release

Share
Shell Offers New AI-Powered Applications Through Open AI Energy Initiative

C3 AI (NYSE:AI) and Shell (NYSE:RDS) today announced three new Shell products that will be available through the Open AI Initiative (OAI), an open ecosystem of artificial intelligence (AI)-based solutions for the energy and process industries.

The OAI, launched by C3 AI, Shell, Baker Hughes and Microsoft in February 2021, provides an open framework for energy operators, service & equipment providers, and independent software vendors to offer interoperable solutions, powered by the BHC3 AI Suite and Microsoft Azure. The three new OAI products – Shell Process Optimiser for LNG, Shell Corrosion Advanced Risk Modelling and Analytics, and Shell Autonomous Integrity Recognition – target use cases that will solve key challenges for businesses in the energy industry. By using Shell’s proven domain-specific AI applications built on BHC3’s scalable AI application development platform and SaaS applications, businesses can rapidly move past data discovery and cleaning to application deployment and realization of value in critical business areas.

Details on the new offerings are outlined below:

  • Shell Process Optimiser for LNG – The application marries state-of-the-art LNG process engineering and technology with data analytics to enhance asset production by helping asset engineers close the gap between current and optimal production (“gap to potential”) by changing key identified operating conditions as optimization levers. The application integrates sensor information, such as pressure, temperature, and flow rate to calculate the optimum setting using custom-built asset machine learning models. It reveals unknown correlations and sweet spots, and derives the best suitable strategies as optimization know-how. The application, capable of handling operational, economic, and engineering constraints, Shell Process Optimiser for LNG generates actionable insights that can be integrated and brought into the continuous closed loop process control layer for sustained benefits realisation.
  • Shell Corrosion Advanced Risk Modelling and Analytics – The application makes use of novel data analytics techniques to predict internal corrosion and erosion to better prioritize and target inspection and maintenance activities. By using a variety of collected site data, and with the help of artificial intelligence, the software provides new insights to predict corrosion and erosion and identify degradation before leaks happen. By using this solution, operators can lower inspection costs and HSSE risk, minimise cost of related leaks, and safely push production to the limit. Additionally, Shell Corrosion Advanced Risk Modelling and Analytics reduces the need for manual, tedious field inspections, resulting in significant time and cost savings.
  • Shell Autonomous Integrity Recognition – The application allows inspectors to quickly and easily make use of automated image capture and evaluation to support execution of external integrity inspections. By processing data in the cloud coming from inspections carried out with handheld devices, drones and robots, the solution enables inspectors to objectively evaluate issues, identify items that have been overlooked, reduce the time needed at the desk generating reports, and improve inputs to maintenance planning. Shell Autonomous Integrity Recognition application allows users to identify and classify external corrosion and insulation issues with Machine Vision to reduce leakages. By using this, users can improve the quality, efficiency, and standardization of visual inspections.

These products expand the portfolio of solutions available to OAI subscribers and help accelerate the adoption of enterprise AI in the energy and process industries.

“Previously, there was no framework for Oil and Gas operators to subscribe to proven AI and advanced analytic solutions offered by other operators,” said C3 AI CEO Thomas M. Siebel. “By bringing more solutions built on the BHC3 AI Suite to the OAI, Shell is demonstrating market leadership and establishing the OAI as a one-of-a-kind model of collaboration.”

These applications also broaden the focus areas of the OAI offerings from asset and system reliability to facility and plant optimization and asset integrity, adding to an expanding portfolio of highly differentiated, domain-specific and proven AI applications and modules that are interoperable. These applications can be deployed together to realize business value and create scalable, futureproof reference architectures.

“The products announced today have already been deployed at Shell and have been proven to either create operational efficiencies and savings or generate additional revenue and opportunity,” said Dan Jeavons, Vice President Computational Science and Digital Innovation at Shell. “As more products are added to the growing OAI eco-system, we look forward to working with C3 AI, Baker Hughes, and the other ecosystem partners to build the next-generation platform for the future energy system.”

About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company that accelerates digital transformation for organizations globally. C3 AI® delivers a family of fully integrated products: C3 AI® Suite , an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications , a portfolio of industry-specific SaaS AI applications; C3 AI CRM , a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina , a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai .

About Royal Dutch Shell plc
Royal Dutch Shell plc is incorporated in England and Wales‚ has its headquarters in The Hague and is listed on the London‚ Amsterdam‚ and New York stock exchanges. Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. For further information, visit www.shell.com . The companies in which Royal Dutch Shell plc directly and indirectly owns investments are separate legal entities. In this document “Shell” is sometimes used for convenience where references are made to Royal Dutch Shell plc and its subsidiaries in general.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye